Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise [Yahoo! Finance]
Cardiol Therapeutics Inc. - Class A Common Shares (CRDL)
Company Research
Source: Yahoo! Finance
Cardiol Therapeutics (NASDAQ:CRDL) is aiming to address inflammation-driven heart disease with therapies the company believes could improve outcomes in conditions that currently have limited or no approved treatment options, President and CEO David Elsley said in an interview with Barchart. Speaking with Barchart Head of Content Kinsey Grant Baker, Elsley described Cardiol's focus in simple terms as targeting “inflammation and how it impacts quality of life and the lives of tens of thousands of people around the world who live with or die from heart disease.” 2023 updates: late-stage transition and two major programs ? 3 Surprising S&P 500 Outperformers of 2026 Elsley characterized 2023 as “a transformational year” for Cardiol, saying the company moved into late-stage development. He highlighted three areas of progress: Initiation of the Phase III MAVERIC program in recurrent pericarditis Reported data from the global ARCHER trial in myocarditis Advancement of what he d
Show less
Read more
Impact Snapshot
Event Time:
CRDL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDL alerts
High impacting Cardiol Therapeutics Inc. - Class A Common Shares news events
Weekly update
A roundup of the hottest topics
CRDL
News
- Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart [Yahoo! Finance]Yahoo! Finance
- Cardiol Therapeutics (CRDL) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $8.00 price target on the stock.MarketBeat
- Cardiol Therapeutics (CRDL) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CRDL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "selMarketBeat
- Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]Yahoo! Finance
CRDL
Sec Filings
- 4/14/26 - Form 6-K
- 4/10/26 - Form 6-K
- 4/1/26 - Form 6-K
- CRDL's page on the SEC website